
Justice Department antitrust officials are looking to find out if a deal to combine the internet’s two largest content-recommendation firms would suppress competition in a market that has provided a steady stream of revenue to online publishers.
The department has been interviewing clients and rivals of Taboola Ltd. and Outbrain Inc., asking detailed questions about whether their combination could be harmful for publishers and online ad networks, according to people familiar with the matter.
Taboola Ltd. in October agreed to buy Outbrain Inc. in a cash-and-stock deal that would have Outbrain shareholders receive $250 million in cash and Taboola stock equivalent to 30% of the combined firm.
Both companies generate “promoted stories” and “around the web” sections that appear next to articles and videos online, unusually at the bottom of a webpage. In essence, the rival firms each rent the basement space on webpages, while some other ad networks, including Alphabet Inc.’s Google, deliver ads in more prominent positions.
Those bottom sections contain a mix of material, including sponsored content and advertisements styled to resemble news stories, usually with tantalizing headlines like “The Best Way to Stop a Barking Dog (It’s Genius)” and “She Had No Clue Why the Crowd Started Cheering.”
The companies have become a mainstay for many digital publishing executives, some of whom rely on regular payments from Taboola and Outbrain.
Outbrain’s clients include CNN, the Guardian and the Washington Post, while Taboola’s clients include Fox News and NBC News. It isn’t known which clients the Justice Department has spoken to.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas